2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 605

Clinical Outcomes of Golimumab As Second Line TNF Inhibitor Treatment in Patients with Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) or Ankylosing Spondylitis (AS) – Subanalysis of a Non-Interventional Study in Germany
Abstract Number: 2760

Clinical Outcomes of Patients with Giant Cell Arteritis Treated with Tocilizumab in Real-World Clinical Practice
Abstract Number: 1493

Clinical Predictor Factors Associated with Sustained Disease Activity Among Patients with Early Rheumatoid Arthritis
Abstract Number: 235

Clinical Predictors and Risk of Methotrexate Induced Liver Fibrosis
Abstract Number: 2406

Clinical Presentation, Management and Long Term Outcome of Pars Planitis (PP), Panuveitis (PU) and Vogt–Koyanagi–Harada Disease (VKH) in Children and Adolescents
Abstract Number: 1450

Clinical Radiology Reports Are Unreliable for Assessment of Radiographic Structural Progression in US Veterans with Rheumatoid Arthritis Initiating Tumor Necrosis Factor Inhibitor Therapy
Abstract Number: 697

Clinical Results of Patients with Peripheral Psoriatic Arthritis Not Receiving Biological Therapy in a Multidisciplinary Unit
Abstract Number: 1776

Clinical Significance of Allergy in IgG4-Related Disease
Abstract Number: 2158

Clinical Significance of Anti-Ro52 Antibody in Chinese Patients with Connective Tissue Diseases: A Single-Center Experience
Abstract Number: 1704

Clinical SLE Disease Activity Index Score of Zero May be a More Pragmatic Outcome Measure in SLE Studies
Abstract Number: 2204

Clinical Utility of a Multi-Energy Spectral CT in Crystal Arthritis
Abstract Number: 1570

Clinical Utility of a Second Minor Salivary Gland Biopsy in Patients with Suspected Sjögren’s Syndrome: A Retrospective Cohort Study
Abstract Number: 1318

Clinical Utility of Ultrasonography (US) in Diagnosing and Monitoring Disease Activity of Relapsing Polychondritis (RP) and Comparison of Cartilaginous US Findings between RP, Repeated Trauma and Healthy Subjects
Abstract Number: 774

Clinical Variables and Serologic Markers of Disease Activity Do Not Aid in Early Recognition of Patients with Tubulointerstitial Disease Who Have No Significant Renal Impairment at Time of Biopsy
Abstract Number: 396

Clinical, Physiologic, and Radiologic Features Associated with Severe MDA5-Associated Interstitial Lung Disease

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].